#United States #patented technology #Exton, Pennsylvania #ProRx #Nanoemulsion

ProRx Pharma Unveils a Game-Changer in Healthcare Delivery

On November 5, 2025, ProRx Pharma, a prominent player in the health and wellness sector, introduced its revolutionary Liquid Nanoemulsion Delivery System. This innovation represents a significant leap forward in how medications are administered, particularly addressing patient needs for convenience and enhanced absorption. As the only 503B outsourcing facility in the U.S. with rights to this patented technology, ProRx opens new avenues for non-injectable therapies.

What is Nanoemulsion Technology?

Nanoemulsion technology involves encapsulating tiny particles in a liquid format, allowing for quicker and easier absorption by the body. By using a lipid-based delivery system, these particles can bypass the stomach and digestive system, entering directly into the bloodstream via tissues located under the tongue or inside the cheek. This method not only minimizes the discomfort associated with traditional injections but also enhances bioavailability, enabling faster therapeutic effects.

According to Kurt Lunkwitz, the Chief Operating Officer at ProRx, “Healthcare providers today are increasingly looking for speedy, reliable therapies that prioritize patient comfort. Our Liquid Nanoemulsion Delivery System offers an innovative way to provide customized formulations from the Bulk Drug Substances list while reducing the reliance on injections.”

Key Features of ProRx's Nanoemulsion Delivery System

1. Improved Bioavailability Potential: The lipid encapsulation method protects therapies from degradation and enhances cellular absorption.

2. Convenience and Compliance: The liquid medication eliminates the need for injections, presenting a straightforward and non-invasive option for patients.

3. Consistent Results Potential: Utilizing nanoemulsion technology helps ensure reproducible absorption with minimized variability across doses.

4. No Refrigeration Necessary: More stable storage conditions further increase convenience for both healthcare providers and patients.

5. Optimized Absorption: The method of sublingual administration allows for a more efficient uptake of the medication into the system.

Faster Therapeutic Effects

The introduction of this new system is particularly timely, as faster absorption could lead to quicker results and better patient outcomes. By providing an alternative to injectable therapies, ProRx enhances the repertoire of options available for preventative health strategies and personalized medicine.

The new Liquid Nanoemulsion Delivery System includes products such as:

• - Sermorelin (1mL daily ampule)
• - NAD+ (1mL daily ampule)
• - Testosterone (1mL daily ampule)

All these offerings are compounded in compliance with strict U.S. Pharmacopeia (USP) <797> and Current Good Manufacturing Practices (cGMP) standards at ProRx’s DEA-registered 503B facility. Each batch undergoes rigorous third-party testing to validate potency, purity, and sterility, ensuring high reliability and performance for patients.

Expert Insights

Testimonials from the medical community reflect the enthusiasm around this new delivery system. Dr. Cindy Zughbi, Medical Director at Vitality Health of South Florida, stated, “For years, we've observed patients hesitant about injectable treatments. These oral therapies provide the opportunity for consistent testosterone levels and high therapeutic efficacy without the discomfort of injections.”

Conclusion

ProRx Pharma's Liquid Nanoemulsion Delivery System marks a transformative step in healthcare, prioritizing patient comfort while maintaining effective treatment protocols. With a focus on safety and innovation, this new system equips healthcare providers with the tools needed to foster better patient outcomes. As ProRx continues its commitment to improving wellness and health, this latest advancement solidifies its position as a leader in the healthcare sector. For ongoing updates and insights, follow ProRx on LinkedIn.

• ---

Sources

1. Dove Press
2. PubMed
3. Frontiers in Pharmacology